Monoisotopic silver nanoparticles‑based mass spectrometry imaging of human bladder cancer tissue: Biomarker discovery

December 2022

Authors: MD, FEBU Anna Ossolińska, MD, PhD, FEBU Tadeusz Ossolinski, MD, PhD, FEBU Krzysztof Ossoliński, Tomasz Ruman 2, Adrian Arendowski 2, Artur Kołodziej 3, Aneta Płaza-Altamer 3, Joanna Nizioł 4

Abstract

Purpose: Bladder cancer (BC) is the 10th most common cancer globally and the second most common urinary tract malignancy. This study used laser desorption/ionization mass spectrometry imaging (LDI‑MSI) with monoisotopic silver‑109 nanoparticle-enhanced target (¹⁰⁹AgNPET) to analyze tumor and adjacent normal tissues in six patients with diagnosed BC.
Results: Statistical analyses identified 10 metabolites that clearly distinguish between tumor and normal tissue. Pathway analysis associated these metabolites with 17 metabolic pathways. Receiver operating characteristic (ROC) analysis showed AUC > 0.99, indicating excellent discriminative performance.
Conclusions: The identified metabolites are promising biomarkers differentiating cancerous vs. healthy bladder tissue, with very high accuracy via LDI‑MSI using ¹⁰⁹AgNPET technology.

Full link below:

Monoisotopic silver nanoparticles-based mass spectrometry imaging of human bladder cancer tissue: Biomarker discovery – PubMed